MACLEODS PHARMS LTD
GenericsMACLEODS PHARMS LTD is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
MACLEODS PHARMS LTD's Key Drugs
MACLEODS PHARMS LTD's core commercial portfolio centers on DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Type 2 Diabetes Mellitus
Hypertension
Hypertension
Hypertension
Heart Failure
MACLEODS PHARMS LTD's Recent FDA Approvals
MACLEODS PHARMS LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MACLEODS PHARMS LTD's Therapeutic Areas
MACLEODS PHARMS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MACLEODS PHARMS LTD's Top Competitors
MACLEODS PHARMS LTD's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MACLEODS PHARMS LTD Pipeline Snapshot
Active clinical trials for MACLEODS PHARMS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (14)
Discontinued (8)
Company Info
- First Approval
- 2012-01-12
- Latest
- 2026-06-23
- Applications
- 174